RxDoctor Payments Data

Tariq Javed, MD

Nephrology · Visalia, CANPI 1891973806

Payments from drug & device makers

$23,003in general payments, 2019–2025

Across 77 payments — averaging $298.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$13K
  • Otsuka America Pharmaceutical, Inc.$9K
  • AstraZeneca$459
  • Johnson & Johnson$186
  • Intercept Pharmaceuticals, Inc.$125
  • Fresenius USA Marketing, Inc.$98
  • plus $418 from 12 others

What the payments were for

  • Speaking & faculty fees$5,93860%
  • Travel & lodging$2,26123%
  • Food & beverage$1,54716%
  • Education$1802%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,003 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$1,147,262
Medicare patients
1,249
Services billed
10,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide118$272,921
FarxigaDapagliflozin Propanediol125$137,341
Sevelamer Hcl46$107,361
LokelmaSodium Zirconium Cyclosilicate103$95,750
XphozahTenapanor Hcl24$70,173
ProcritEpoetin Alfa84$59,693
Sevelamer Carbonate220$52,974
ProsolParenteral Amino Acid 20% No.1197$33,602
JardianceEmpagliflozin31$29,286
VeltassaPatiromer Calcium Sorbitex20$24,731
RetacritEpoetin Alfa-Epbx46$22,256
Calcium Acetate213$18,120
ClinolipidFat Emulsion/Olive/Soy/Phospho57$14,580
Lanthanum Carbonate17$13,319
JanuviaSitagliptin Phosphate11$10,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$98$272,921118 claims
AstraZenecaFarxiga, Lokelma$459$233,091228 claims
Johnson & JohnsonProcrit$186$59,69384 claims
PfizerRetacrit$45$22,25646 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.

Other nephrology in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →